menu search

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic ...

November 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic ...

November 3, 2023, 8:30 pm

Scancell melanoma trial data chosen for poster presentation at sitc

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors that it has been selected for a poster presentation of data from the first stage of its Pha...

November 1, 2023, 4:16 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Scancell to speak at prestigious vaccine event

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), which is developing immunotherapies for cancer and infectious disease, said its chief executive and chie...

October 18, 2023, 3:14 am

Gritstone bio: renewed excitement for its covid-19 vaccine

GRTS's COVID-19 vaccine may produce more durable immunity than current mRNA vaccines, according to data from phase 1 studies. GRTS has secured a $433 ...

October 14, 2023, 2:21 am

Io biotech announces three poster presentations at the society for immunotherapy of cancer’s (sitc) 38th annual meeting

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary data including promising relapse-free survival data from the phase 1 study of eli-002 at aacr special conference: pancreatic cancer

ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G...

September 27, 2023, 9:30 pm

Immatics inks deal worth $120m to $1.7b with moderna to boost cancer vaccine development

Immatics NV's shares rose Monday after it announced a collaboration with Moderna Therapeutics Inc (NASDAQ:MRNA) to pioneer novel and transformative t...

September 11, 2023, 11:31 am

Moderna, immatics to work jointly on cancer vaccines

Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines ...

September 11, 2023, 7:32 am

Io biotech announces participation in upcoming investor conferences

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

September 6, 2023, 8:35 am

Io biotech appoints heidi hunter to its board of directors

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

August 11, 2023, 12:05 pm

World renowned biomedical professor jonathan lakey joins cancervax board of advisors

Dr. Lakey has been recognized nationally and internationally for his groundbreaking research in cell and tissue transplantation for patients suffering...

July 27, 2023, 2:01 am

Is moderna stock a buy as it doubles down on its cancer vaccine efforts?

Is Moderna stock a buy after unveiling new results for its Merck-partnered cancer vaccine? Is MRNA stoc...

June 29, 2023, 2:34 pm

Why curevac stock leaped 12% higher today

The European biotech delivered some promising news from the laboratory. It has dosed its first patient in a crucial phase 1 trial of its ...

June 20, 2023, 6:29 pm

Biotech executive michael smith discusses the fda drug development process with cancervax ceo ryan davies

Michael Smith comments on the growth of immunotherapy and sees the required FDA development phases as a benefit to small biotech firms such as CancerV...

June 16, 2023, 7:01 am


Search within

Pages Search Results: